Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hsct in Patients With Hemoglobinopathies Publisher



Rostami T1 ; Kiumarsi A2 ; Mohseni M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hematologic Malignancies Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Science, Tehran, Iran
  2. 2. Children's Medical Center Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Source: Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation Published:2024


Abstract

Hemoglobinopathies, are a group of monogenic inherited disorders that affect the structure or production of the globin chains. Improvements in red blood cell transfusion management and its potential complications have influenced the prognosis of patients. However cardiovascular disease Cardiovascular disease represents the leading etiology of morbidity and mortality in thalassemia Thalassemia, as well as a main determinant of prognosis in Sickle cell disease SCD. In spite of noteworthy advances in medical care for severe hemoglobinopathies, allogeneic HSCT Allogeneic HSCT remains the only definitive treatment available. This chapter aims to discuss the cardiovascular considerations of patients with hemoglobinopathies in the setting of hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation (HSCT). © Springer Nature Switzerland AG 2024. All rights reserved.